Advertisement

ADVERTISEMENT

loperamide

Research in Review
Prophylactic Treatment Reduces Toxicity in HER2+ Breast Cancer
01/11/2017
JCP Editors
Loperamide plus budesonide reduces the rate of toxic effects associated with neratinib for patients with human epidermal growth factor receptor-2 positive (HER2+) breast cancer, according to the results of a trial...
Loperamide plus budesonide reduces the rate of toxic effects associated with neratinib for patients with human epidermal growth factor receptor-2 positive (HER2+) breast cancer, according to the results of a trial...
...
01/11/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Derm Week
November 13 ⁠–⁠ November 16
Dermatology Week
November 13 ⁠–⁠ November 16
Psych Congress Primary Care Online Series
November 14 ⁠–⁠ November 15
November 23 ⁠–⁠ November 24
December 4 ⁠–⁠ December 5
Great Debates & Updates in Diabetic Foot
December 6 ⁠–⁠ December 7
December 9 ⁠–⁠ December 11
AIBD logo
December 9 ⁠–⁠ December 11
Psych Congress Primary Care Online Series
December 12 ⁠–⁠ December 13
December 14 ⁠–⁠ December 15
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use